Gates Foundation joins $26M round for developer of flu drug

11/12/2012 | Mass High Tech (Boston) · Xconomy

Visterra secured an additional $13 million in a Series A funding round from existing and new investors, bringing the total raised to $26 million. The biotech startup will use the money to advance VIS410, an antibody to prevent and treat influenza, into clinical development.

View Full Article in:

Mass High Tech (Boston) · Xconomy

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Actuary
Meridian Health Plan
Detroit, MI